🔗 Share this article

An underground market for unapproved slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Investigational Drug Gaining Popularity Via Social Media

The experimental drug, which is still in research studies, is being promoted by online personalities for its alleged fat-burning effects. Viewers are urged to contact these profiles privately for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Separately, a flourishing market exists on messaging services, where groups with numerous of participants share “before and after” photos, injection guides and claims of next-day British shipping. Sellers market the drug there before directing customers to WhatsApp for purchases.

Understanding Retatrutide

Retatrutide is an investigational injection developed by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.

Healthcare Experts Express Worries

Nevertheless, doctors and chemists have warned that the sale of what is still an unlicensed medication in the UK is a cause for concern and could lead to users administering products of uncertain source.

Several professionals said the popularity for the experimental drug could be connected to the rising price of approved weight loss treatments such as Mounjaro.

Legal Position and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or distributed for personal consumption under the British medical regulations.

Several content creators try to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate pharmaceutical, marketing, and consumer regulations, risking penalties, prosecution or imprisonment.

Platform Reaction and Material Elimination

Based on the social media company, the service has taken down violative material and banned related hashtags and search suggestions. The company said it was dedicated to keeping the service safe and investing in enhancing enforcement strategies.

Online Marketplace Activities

Research also found groups with up to nine thousand members marketing retatrutide using Telegram's integrated discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays groups with numerous of members, filled with photos of weight loss, positive reviews and detailed instructions for preparing or injecting at home.

Within moments of joining one group, a seller shared WhatsApp details, where the majority of transactions occur. The seller provided an instruction manual and guaranteed shipping within two days. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another shared a photo of a alleged testing documentation. Not one inquired about weight, medical conditions or past usage.

Product Information and Pricing

Within these communities, messages display black plastic parcels with postal service labels, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with sterile water, or pre-filled pens usually priced at £160 for 20mg. When asked how much time a pen should be used, vendors give contradictory responses varying between a few weeks to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for the messaging service stated it regularly moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the science behind this drug is sound, these digital versions may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor linked the surge in demand to recent cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was clean,” she explained.

Her staff has already seen patients injured by personal administration from unverified suppliers. “We recognize the disappointment, but buying from messaging apps or communication platforms is taking chances with your health,” said Wyllie. “These substances could be impure or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this time no one can market [it] for human use,” they said, adding that any product “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may expose users to potentially significant health risks”.